Drug Trial Radar · NCT03394365
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Dec 29, 2017
Primary completion
May 31, 2030
Study completion Aug 2030
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Jan 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Solid Organ Transplant Complications
- Lymphoproliferative Disorders
- Allogeneic Hematopoietic Cell Transplant
- Stem Cell Transplant Complications
Interventions
tabelecleucelBiological
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in the Analysis Cohorts C-SOT, C-HCT, and Combined Population (C-SOT-R+C, C-SOT-R-Ci, and C-HCT) Who Received Commercial Product, or a Product Manufactured Using a Comparable PVTime frame: 2 years
Locations
71 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope (Adults and Pediatrics)
Duarte, California · Completed
University of California San Diego Moores Cancer Center (Adults only)
La Jolla, California · Completed
Loma Linda University Medical Center (Adults only)
Loma Linda, California · Recruiting
Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics)
Los Angeles, California · Recruiting
UCLA Medical Center (Adults and Pediatrics)
Los Angeles, California · Completed
University of California Davis Comprehensive Cancer Center (Adults only)
Sacramento, California · Completed
Yale University (Adults and Pediatrics)
New Haven, Connecticut · Completed
MedStar Georgetown University Hospital (Adults and Pediatrics)
Washington D.C., District of Columbia · Recruiting
University of Florida (Adults and Pediatrics)
Gainesville, Florida · Completed
University of Miami/Jackson Memorial Hospital (Adults only)
Miami, Florida · Recruiting
Winship Cancer Institute (Adults only)
Atlanta, Georgia · Completed
Arthur M Blank Hospital - Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics)
Chicago, Illinois · Recruiting
University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only)
Chicago, Illinois · Completed
Loyola University Medical Center (Adults and Pediatrics)
Maywood, Illinois · Recruiting
University of Maryland School of Medicine (Adults only)
Baltimore, Maryland · Completed
Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)
Boston, Massachusetts · Recruiting
Washington University School of Medicine (Adults only)
St Louis, Missouri · Recruiting
Weill Cornell Medicine (Adults only)
New York, New York · Completed
Columbia University Medical Center (Adults and Pediatrics)
New York, New York · Completed
Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)
New York, New York · Completed
Montefiore Medical Center (Adults only)
The Bronx, New York · Completed
Montefiore Medical Center (Pediatrics only)
The Bronx, New York · Completed
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics)
Chapel Hill, North Carolina · Completed
Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics)
Charlotte, North Carolina · Recruiting
Duke Cancer Institute (Adults and Pediatrics)
Durham, North Carolina · Recruiting
Cleveland Clinic Foundation (Adults and Pediatrics)
Cleveland, Ohio · Recruiting
Nationwide Children's Hospital (Pediatrics only)
Columbus, Ohio · Completed
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics)
Columbus, Ohio · Recruiting
Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics)
Portland, Oregon · Recruiting
Hospital of the University of Pennsylvania (Adults only)
Philadelphia, Pennsylvania · Recruiting
The Children's Hospital of Philadelphia Oncology Division, Blood & Marrow Transplant Section (Pediatrics)
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center (Adults only)
Pittsburgh, Pennsylvania · Completed
Medical University of South Carolina (Adults and Pediatrics)
Charleston, South Carolina · Completed
Saint Jude Children's Research Hospital (Pediatrics only)
Memphis, Tennessee · Completed
Vanderbilt University Medical Center Henry-Joyce Cancer Clinic (Adults and Pediatrics)
Nashville, Tennessee · Recruiting
Baylor Scott and White Research Institute (Adults only)
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only)
Dallas, Texas · Recruiting
MD Anderson Cancer Center (Pediatrics and Adult)
Houston, Texas · Recruiting
Froedtert and Medical College of Wisconsin - Clinical Cancer Center (Adults only)
Milwaukee, Wisconsin · Completed
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.